New publication date for Modus Therapeutics’ interim report for the first quarter
Stockholm, Sweden–April 22[th] 2022: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby announces that the publication of the company's Q1 report will take place on May 16, 2022. The previously announced date was May 9, 2022.For more information on Modus Therapeutics, please contact: John Öhd, VD, Modus Therapeutics Telefon: +46 (0) 70 766 80 97 E-post: john.ohd@modustx.com Certified Adviser Svensk Kapitalmarknadsgranskning AB Telefon: +46 11 32 30 732 E-post: ca@skmg.se *** About Modus Therapeutics and sevuparin Modus Therapeutics is a Swedish